《Business Times》AmCad and Swiss Doctor presented study results at ISSS 2024
24-01-31
Dr. Kurt Tschopp of Kantonsspital Baselland in Switzerland and AmCad BioMed presented the results of their study at the International Surgical Sleep Society Annual Meeting in Australia.
AmCad BioMed (ticker 4188) has partnered with Dr. Tschopp to use its ultrasound AI technology to predict the effectiveness of hypoglossal nerve stimulation therapy for obstructive sleep apnea (OSA). AmCAD-UO analyzes upper airway tissue structure to predict responsiveness to the hypoglossal nerve stimulator with predictive value as high as 80%, potentially saving costs and improving treatment outcomes.
Source: "Business Times" AmCad BioMed partnered with Swiss doctor to present results at ISSS Annual Meeting in Australia”
are the trademarks owned by AmCad in Taiwan and/or in other countries. Unauthorized use of the AmCAD trademarks is prohibited unless specifically authorized.